Cullinan Therapeutics

Cullinan Therapeutics has developed a broad range of modalities, each with the potential to be best-in-class or first-in-class. Anchored in a deep understanding of oncology, immunology, and translational medicine, the company creates differentiated ideas, identifies appropriate targets, and selects the optimal modality to develop transformative therapeutics across various cancer and autoimmune indications.

Cullinan employs a rigorous evaluation process, applying stringent go/no-go criteria at each development stage to advance only the most promising molecules to the clinic and, ultimately, commercialization. With deep scientific expertise, the company's teams exercise creativity and urgency to deliver new therapeutic solutions to patients.

The company's portfolio includes several clinical-stage assets, such as CLN-619, a potential first-in-class anti-MICA/B antibody being studied in solid tumors and hematological malignancies. CLN-978, a CD19xCD3 T-cell engager, is being developed for autoimmune diseases, starting with systemic lupus erythematosus (SLE). Additionally, Cullinan has a collaboration with Taiho Oncology for zipalertinib, an EGFR exon20 insertion inhibitor for non-small cell lung cancer (NSCLC).

Cullinan Therapeutics operates as a publicly listed company and is listed on Nasdaq under the ticker symbol CGEM.

Key customers and partnerships

Cullinan Therapeutics has established partnerships and collaborations to advance its product candidates. The company's notable collaboration is with Taiho Oncology for the development and commercialization of zipalertinib in NSCLC. Under the agreement, Cullinan received an upfront payment of USD 275 million and is eligible for additional regulatory milestone payments totaling USD 130 million, as well as a 50/50 profit share in the US market.

Furthermore, the company has entered into partnerships with academic institutions and research organizations to support its drug development efforts, leveraging their expertise and resources. However, the sources provided do not disclose specific details about Cullinan's other partnerships or key customers.